ClinicalTrials.gg
CompletedNCT04903093Updated Nov 14, 2024Results posted

A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.

A Phase 1 interventional study of Abrocitinib tablet and Abrocitinib Suspension F1 in Healthy Volunteers, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-14.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing abrocitinib in Dermatitis, Atopic — 5 open to participants now, 5 under way, 2 of them phase 3. abrocitinib · Dermatitis, Atopic.

Enrollment
18th of 20
19 · median 150
Started
2021
the only one that year
Phase 1
3 of 20
none open now
Registered
12th of 20
by date
Lead sponsor
15 of 20
Pfizer

Among the 20 studies testing abrocitinib in Dermatitis, Atopic, this one is the 18th largest by enrollment, is the only one that started in 2021, is one of 3 in phase 1, and was the 12th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

5 of the 20 studies testing abrocitinib in Dermatitis, Atopic are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About abrocitinib

abrocitinib: first FDA approval 2022 (CIBINQO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing abrocitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This study consists of 2 parts: Part A is to estimate the relative bioavailability of a single 200 mg dose of abrocitinib oral suspension (Test formulation) compared to the commercial abrocitinib tablet (200 mg) (Reference formulation). The effect of an acid-reducing agent on the pharmacokinetics of abrocitinib and its metabolites will also be evaluated by administering abrocitinib 200 mg commercial tablet with or without famotidine 40 mg, as an acid-reducing agent. Part B is to assess the taste and palatability of six different abrocitinib oral suspension formulations. Additionally, the safety and tolerability of abrocitinib tablet (in Part A) and abrocitinib oral suspension formulations (in Part B) will be assessed when given with or without famotidine 40 mg once daily.

Read the detailed description

This is a Phase 1 randomized study in healthy participants to estimate the relative bioavailability of abrocitinib oral suspension (Test formulation) compared to commercial abrocitinib tablet (Reference formulation) under fasted condition. The effect of an acid-reducing agent on the pharmacokinetics of the commercial tablet formulation will be evaluated by administering abrocitinib 200 mg commercial tablet with famotidine 40 mg, as an acid-reducing agent. Assessment of taste and palatability of six different abrocitinib suspension formulations will also be performed. This study consists of 2 parts, as listed below:

Part A

Part A of the study will be an open label, randomized, single dose, crossover, 3-treatment, 6 sequence, 3-period design in healthy male and/or female adult participants (18-55 years). Healthy participants will be screened within 28 days prior to the first administration of the study intervention to confirm that they meet the participant selection criteria for the study. Eligible participants will be admitted to the CRU on Day -1 and will be confined in the CRU until discharge, on Day 2 of Period 9 in Part B, after completing both Parts A and B of the study. In Part A, participants will be randomized to receive one of the following: a single 200 mg dose of abrocitinib commercial tablet (Treatment A), a single 200 mg dose of abrocitinib oral suspension formulation 1 (Treatment B), or famotidine (40 mg) administered 120 minutes before a single 200 mg dose of abrocitinib commercial tablet (Treatment C). All participants will be fasting for at least 10 hours before taking abrocitinib.

Part B

Part B will be a single-blind, randomized, 6-period, crossover study in healthy male and/or female adult participants (18-55 years). For any new healthy participants joining Part B only, screening will be performed within 28 days prior to the first administration of the study intervention to confirm that they meet the participant selection criteria for the study. New participants enrolled in Part B only will be admitted to the CRU on Day -1 and will be confined in the CRU until discharge, which is Day 2 of Period 9. On Day 1 of each treatment period under fasted conditions, participants will receive a famotidine tablet (40 mg with 240 mL of room temperature water) administered 120 minutes before a single 200 mg dose of abrocitinib oral suspensions (Formulations 1 to 6) or administered a single 200 mg dose of abrocitinib oral suspension alone (Formulations 1 to 6), after a fast of at least 10 hours before abrocitinib administration.

03

Conditions studied

  • Healthy Volunteers

Browse trials for

Keywords

  • Abrocitinib
  • Atopic Dermatitis
  • Healthy Volunteers
  • Relative Bioavailability
  • Taste Assessment
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants who are overtly healthy as determined by medical evaluation including a detailed medical history, complete physical examination, laboratory tests, and cardiovascular tests.
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
  • Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
  • Any condition possibly affecting drug absorption (eg, gastrectomy).
  • History of (HIV), virus, or virus infection; positive testing for HIV, hepatitis B surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb), or hepatitis C virus antibody (HCVAb).
  • Other acute or chronic medical or psychiatric condition including recent (within the past year).

Evidence or history of clinically significant dermatological condition (eg, atopic dermatitis or psoriasis) or visible rash present during physical examination.

  • Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of product.
  • A positive urine drug test.
  • Selected laboratory abnormalities.
  • History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
  • History of tuberculosis (TB) (active or latent).
  • Any history of chronic infections, any history of recurrent infections, any history of latent infections, or any acute infection within 2 weeks of baseline.
  • Pregnant female participants; breastfeeding female participants; female participants of who are unwilling or unable to use an acceptable method of .
  • History of disseminated herpes zoster, or disseminated herpes simplex, or recurrent localized dermatomal herpes zoster.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Part A: Abrocitinib Tablet

    Drug: Abrocitinib tablet

  • Experimental
    Part A: Abrocitinib Suspension F1

    Drug: Abrocitinib Suspension F1

  • Experimental
    Part A: Abrocitinib Tablet + Famotidine

    Drug: Famotidine

  • Experimental
    Part B: Abrocitinib Suspension F1

    Drug: Abrocitinib Suspension F1

  • Experimental
    Part B: Abrocitinib Suspension F2

    Drug: Abrocitinib Suspension F2

  • Experimental
    Part B: Abrocitinib Suspension F3

    Drug: Abrocitinib Suspension F3

  • Experimental
    Part B: Abrocitinib Suspension F4

    Drug: Abrocitinib Suspension F4

  • Experimental
    Part B: Abrocitinib Suspension F5

    Drug: Abrocitinib Suspension F5

  • Experimental
    Part B: Abrocitinib Suspension F6

    Drug: Abrocitinib Suspension F6

  • Experimental
    Part B: Abrocitinib Suspension F1 + Famotidine

    Drug: Abrocitinib Suspension F1 · Drug: Famotidine

  • Experimental
    Part B: Abrocitinib Suspension F2 + Famotidine

    Drug: Abrocitinib Suspension F2 · Drug: Famotidine

  • Experimental
    Part B: Abrocitinib Suspension F3 + Famotidine

    Drug: Abrocitinib Suspension F3 · Drug: Famotidine

  • Experimental
    Part B: Abrocitinib Suspension F4 + Famotidine

    Drug: Abrocitinib Suspension F4 · Drug: Famotidine

  • Experimental
    Part B: Abrocitinib Suspension F5 + Famotidine

    Drug: Abrocitinib Suspension F5 · Drug: Famotidine

  • Experimental
    Part B: Abrocitinib Suspension F6 + Famotidine

    Drug: Abrocitinib Suspension F6 · Drug: Famotidine

Interventions

  • Single dose of abrocitinib 200 mg tablet will be administered after an overnight fast of at least 10 hours.

  • DrugAbrocitinib Suspension F1

    Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.

  • DrugAbrocitinib Suspension F2

    Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.

  • DrugAbrocitinib Suspension F3

    Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.

  • DrugAbrocitinib Suspension F4

    Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.

  • DrugAbrocitinib Suspension F5

    Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.

  • DrugAbrocitinib Suspension F6

    Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.

  • DrugFamotidine

    Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.

06

What researchers measure

Primary outcomes

  1. AUCinf of Abrocitinib Following the Administration of Abrocitinib Commercial Tablet, Abrocitinib Oral Suspension Formulation 1 or Famotidine Plus Abrocitinib Commerical Tablet

    Area under the plasma concentration time profile from time 0 extrapolated to infinity (AUCinf) was measured. The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.

  2. Cmax of Abrocitinib Following the Administration of Abrocitinib Commercial Tablet, Abrocitinib Oral Suspension Formulation 1 or Famotidine Plus Abrocitinib Commerical Tablet

    Maximum observed plasma concentration (Cmax) was measured. The adjusted mean differences and 90% CIs for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.

  3. Assessment of Overall Liking After Administering Each Abrocitinib Oral Suspension Formulation (Formulation [F]1-F6) in Part B

    For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

    Time frame: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.

  4. Assessment of Mouth Feel After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B

    For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

    Time frame: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.

  5. Assessment of Bitterness After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B

    For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

    Time frame: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.

  6. Assessment of Tongue/Mouth Burn After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B

    For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

    Time frame: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.

  7. Assessment of Salty Taste After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B

    For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

    Time frame: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.

  8. Assessment of Sour Taste After Administering Abrocitinib Oral Suspension Formulation (F1-F6) in Part B

    For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

    Time frame: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.

  9. Assessment of Sweet Taste After Administering Abrocitinib Oral Suspension Formulation (F1-F6) in Part B

    For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

    Time frame: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.

Secondary outcomes

  1. AUCinf of Abrocitinib Metabolite (PF-06471658/M1) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A

    Area under the plasma concentration time profile from time 0 extrapolated to infinity.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.

  2. AUCinf of Abrocitinib Metabolite (PF-07055087/M2) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A

    Area under the plasma concentration time profile from time 0 extrapolated to infinity.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.

  3. AUCinf of Abrocitinib Metabolite (PF-07054874/M4) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A

    Area under the plasma concentration time profile from time 0 extrapolated to infinity.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.

  4. Cmax of Abrocitinib Metabolite (PF-06471658/M1) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A

    Maximum observed plasma concentration.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.

  5. Cmax of Abrocitinib Metabolite (PF-07055087/M2) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A

    Maximum observed plasma concentration.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.

  6. Cmax of Abrocitinib Metabolite (PF-07054874/M4) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A

    Maximum observed plasma concentration.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.

  7. Number of Participants With Treatment-Emergent Adverse Event

    Adverse events (AEs): any untoward medical occurrence in a clinical investigation participant administered a product, without regard to relatedness. Treatment-emergent AEs (TEAEs): AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Treatment-related TEAEs were any untoward medical occurrence attributed to study intervention. Relatedness to study intervention was determined by the investigator.

    Time frame: Baseline up to follow-up (Day 36)

  8. Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)

    Participants with laboratory abnormalities (without regard to baseline abnormality) were reported.

    Time frame: Baseline up to follow-up (Day 36)

  9. Number of Participants With Clinically Significant Vital Sign Values

    Participants with clinically significant vital sign values were reported.

    Time frame: Baseline up to follow-up (Day 36)

  10. Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Values

    Participants with clinically significant abnormal ECG values were reported.

    Time frame: Baseline up to follow-up (Day 36)

  11. Number of Participants With Nausea AEs

    Number of participants who received abrocitinib 200 mg alone and who received abrocitinib 200 mg plus famotidine 40 mg and had nausea AEs were reported.

    Time frame: Baseline up to follow-up (Day 36)

07

Results

Posted Nov 14, 2024

Participant flow

Participant flow — Overall Study
MilestoneTreatment A-> B-> C-> D-> E-> F-> G-> H-> ITreatment A-> C-> B-> L-> M-> N-> B-> J-> KTreatment B-> A-> C-> K-> L-> M-> N-> B-> JTreatment B-> C-> A-> I-> D-> E-> F-> G-> HTreatment C-> A-> B-> H-> I-> D-> E-> F-> GTreatment C-> B-> A-> J-> K-> L-> M-> N-> B
Started333433
Completed333333
Not completed000100
Withdrew: Withdrawal by subject000100

Outcome measures

PrimaryAUCinf of Abrocitinib Following the Administration of Abrocitinib Commercial Tablet, Abrocitinib Oral Suspension Formulation 1 or Famotidine Plus Abrocitinib Commerical Tablet

Area under the plasma concentration time profile from time 0 extrapolated to infinity (AUCinf) was measured. The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
AUCinf of Abrocitinib Following the Administration of Abrocitinib Commercial Tablet, Abrocitinib Oral Suspension Formulation 1 or Famotidine Plus Abrocitinib Commerical Tablet
nanogram*hour per milliliter (ng*hr/mL)Abrocitinib 200 mg Commercial TabletAbrocitinib 200 mg Oral Suspension Formulation 1Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet
AUCinf of Abrocitinib Following the Administration of Abrocitinib Commercial Tablet, Abrocitinib Oral Suspension Formulation 1 or Famotidine Plus Abrocitinib Commerical Tablet4623 ± 664601 ± 543096 ± 61
Statistical analysis
  • Abrocitinib 200 mg Commercial Tablet vs Abrocitinib 200 mg Oral Suspension Formulation 1 · Ratio (%) of adjusted geometric means: 96.96 · 90% CI 85.43 to 110.03
  • Abrocitinib 200 mg Commercial Tablet vs Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet · Ratio (%) of adjusted geometric means: 62.87 · 90% CI 54.85 to 72.07
PrimaryCmax of Abrocitinib Following the Administration of Abrocitinib Commercial Tablet, Abrocitinib Oral Suspension Formulation 1 or Famotidine Plus Abrocitinib Commerical Tablet

Maximum observed plasma concentration (Cmax) was measured. The adjusted mean differences and 90% CIs for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Cmax of Abrocitinib Following the Administration of Abrocitinib Commercial Tablet, Abrocitinib Oral Suspension Formulation 1 or Famotidine Plus Abrocitinib Commerical Tablet
nanogram per milliliter (ng/mL)Abrocitinib 200 mg Commercial TabletAbrocitinib 200 mg Oral Suspension Formulation 1Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet
Cmax of Abrocitinib Following the Administration of Abrocitinib Commercial Tablet, Abrocitinib Oral Suspension Formulation 1 or Famotidine Plus Abrocitinib Commerical Tablet1264 ± 671218 ± 56189.1 ± 77
Statistical analysis
  • Abrocitinib 200 mg Commercial Tablet vs Abrocitinib 200 mg Oral Suspension Formulation 1 · Ratio (%) of adjusted geometric means: 100.07 · 90% CI 80.28 to 124.74
  • Abrocitinib 200 mg Commercial Tablet vs Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet · Ratio (%) of adjusted geometric means: 15.53 · 90% CI 12.46 to 19.36
PrimaryAssessment of Overall Liking After Administering Each Abrocitinib Oral Suspension Formulation (Formulation [F]1-F6) in Part B

For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

Time frame:
0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.
Reported as:
Mean · Units on a scale
Assessment of Overall Liking After Administering Each Abrocitinib Oral Suspension Formulation (Formulation [F]1-F6) in Part B
Units on a scaleAbrocitinib 200 mg Oral Suspension Formulation 1Abrocitinib 200 mg Oral Suspension Formulation 2Abrocitinib 200 mg Oral Suspension Formulation 3Abrocitinib 200 mg Oral Suspension Formulation 4Abrocitinib 200 mg Oral Suspension Formulation 5Abrocitinib 200 mg Oral Suspension Formulation 6
0 Hours42.32 ± 35.11772.10 ± 24.24344.95 ± 34.42242.19 ± 34.36671.08 ± 27.49169.29 ± 27.565
5 min40.21 ± 35.48069.59 ± 25.88242.83 ± 34.54940.32 ± 32.69171.87 ± 24.19067.34 ± 27.632
10 min37.78 ± 34.02565.65 ± 26.85738.86 ± 30.80833.90 ± 29.54467.78 ± 24.91962.89 ± 30.153
20 min35.55 ± 33.37964.48 ± 27.64437.56 ± 29.75831.97 ± 29.56361.68 ± 28.68157.95 ± 28.483
PrimaryAssessment of Mouth Feel After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B

For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

Time frame:
0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.
Reported as:
Mean · Units on a scale
Assessment of Mouth Feel After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B
Units on a scaleAbrocitinib 200 mg Oral Suspension Formulation 1Abrocitinib 200 mg Oral Suspension Formulation 2Abrocitinib 200 mg Oral Suspension Formulation 3Abrocitinib 200 mg Oral Suspension Formulation 4Abrocitinib 200 mg Oral Suspension Formulation 5Abrocitinib 200 mg Oral Suspension Formulation 6
0 Hours40.12 ± 28.33661.59 ± 26.21840.79 ± 33.90842.10 ± 30.17863.59 ± 25.54461.59 ± 31.543
5 min37.26 ± 27.90354.22 ± 26.73837.81 ± 33.04538.67 ± 27.68861.21 ± 25.33560.48 ± 30.987
10 min35.61 ± 29.45650.57 ± 26.57835.18 ± 33.22231.90 ± 24.80855.33 ± 27.45152.36 ± 31.626
20 min34.95 ± 30.34742.22 ± 30.67634.83 ± 33.22126.89 ± 23.27749.27 ± 29.35644.33 ± 32.906
PrimaryAssessment of Bitterness After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B

For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

Time frame:
0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.
Reported as:
Mean · Units on a scale
Assessment of Bitterness After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B
Units on a scaleAbrocitinib 200 mg Oral Suspension Formulation 1Abrocitinib 200 mg Oral Suspension Formulation 2Abrocitinib 200 mg Oral Suspension Formulation 3Abrocitinib 200 mg Oral Suspension Formulation 4Abrocitinib 200 mg Oral Suspension Formulation 5Abrocitinib 200 mg Oral Suspension Formulation 6
0 Hours39.25 ± 30.77364.25 ± 27.31232.06 ± 27.38328.63 ± 21.63470.76 ± 27.86963.28 ± 23.400
5 min36.54 ± 32.00853.30 ± 30.39231.14 ± 27.87525.21 ± 19.68563.62 ± 26.14157.77 ± 28.066
10 min33.80 ± 31.60947.72 ± 31.06727.27 ± 25.12420.95 ± 19.00053.65 ± 25.65749.41 ± 26.827
20 min30.83 ± 31.59839.24 ± 31.32524.92 ± 23.04818.19 ± 19.55445.56 ± 30.63542.37 ± 27.755
PrimaryAssessment of Tongue/Mouth Burn After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B

For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

Time frame:
0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.
Reported as:
Mean · Units on a scale
Assessment of Tongue/Mouth Burn After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B
Units on a scaleAbrocitinib 200 mg Oral Suspension Formulation 1Abrocitinib 200 mg Oral Suspension Formulation 2Abrocitinib 200 mg Oral Suspension Formulation 3Abrocitinib 200 mg Oral Suspension Formulation 4Abrocitinib 200 mg Oral Suspension Formulation 5Abrocitinib 200 mg Oral Suspension Formulation 6
0 Hours28.90 ± 26.48941.87 ± 30.23825.87 ± 23.92026.89 ± 25.88435.75 ± 30.84841.05 ± 32.462
5 min24.48 ± 25.22635.40 ± 28.45122.86 ± 22.47722.67 ± 24.99928.76 ± 25.80937.89 ± 33.134
10 min23.73 ± 26.63131.24 ± 26.30518.29 ± 20.00118.29 ± 22.99922.82 ± 25.04236.99 ± 32.737
20 min21.65 ± 28.93723.97 ± 26.38615.40 ± 20.15616.51 ± 22.37417.68 ± 21.92733.68 ± 32.903
PrimaryAssessment of Salty Taste After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B

For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

Time frame:
0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.
Reported as:
Mean · Units on a scale
Assessment of Salty Taste After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B
Units on a scaleAbrocitinib 200 mg Oral Suspension Formulation 1Abrocitinib 200 mg Oral Suspension Formulation 2Abrocitinib 200 mg Oral Suspension Formulation 3Abrocitinib 200 mg Oral Suspension Formulation 4Abrocitinib 200 mg Oral Suspension Formulation 5Abrocitinib 200 mg Oral Suspension Formulation 6
0 Hours19.73 ± 26.87239.52 ± 31.19019.84 ± 21.56021.84 ± 21.31939.24 ± 30.96234.98 ± 31.103
5 min19.34 ± 27.43535.56 ± 28.37213.78 ± 17.27619.49 ± 22.50433.43 ± 24.68830.92 ± 30.413
10 min19.43 ± 27.77629.49 ± 26.60212.29 ± 17.12115.94 ± 21.41425.33 ± 22.85331.85 ± 33.229
20 min19.61 ± 27.87225.62 ± 26.61312.35 ± 17.23415.68 ± 21.29020.89 ± 19.44428.60 ± 28.337
PrimaryAssessment of Sour Taste After Administering Abrocitinib Oral Suspension Formulation (F1-F6) in Part B

For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

Time frame:
0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.
Reported as:
Mean · Units on a scale
Assessment of Sour Taste After Administering Abrocitinib Oral Suspension Formulation (F1-F6) in Part B
Units on a scaleAbrocitinib 200 mg Oral Suspension Formulation 1Abrocitinib 200 mg Oral Suspension Formulation 2Abrocitinib 200 mg Oral Suspension Formulation 3Abrocitinib 200 mg Oral Suspension Formulation 4Abrocitinib 200 mg Oral Suspension Formulation 5Abrocitinib 200 mg Oral Suspension Formulation 6
0 Hours25.44 ± 26.34352.54 ± 27.70324.86 ± 24.66325.65 ± 22.45248.35 ± 34.21047.37 ± 33.103
5 min24.54 ± 26.91946.32 ± 28.17221.75 ± 23.84921.71 ± 22.19841.02 ± 31.65239.73 ± 32.655
10 min23.16 ± 27.07442.44 ± 29.89218.70 ± 21.87919.18 ± 20.65233.30 ± 31.79736.33 ± 32.522
20 min21.68 ± 27.37337.05 ± 30.42616.95 ± 21.47218.16 ± 20.24128.98 ± 31.33834.31 ± 31.151
PrimaryAssessment of Sweet Taste After Administering Abrocitinib Oral Suspension Formulation (F1-F6) in Part B

For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

Time frame:
0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.
Reported as:
Mean · Units on a scale
Assessment of Sweet Taste After Administering Abrocitinib Oral Suspension Formulation (F1-F6) in Part B
Units on a scaleAbrocitinib 200 mg Oral Suspension Formulation 1Abrocitinib 200 mg Oral Suspension Formulation 2Abrocitinib 200 mg Oral Suspension Formulation 3Abrocitinib 200 mg Oral Suspension Formulation 4Abrocitinib 200 mg Oral Suspension Formulation 5Abrocitinib 200 mg Oral Suspension Formulation 6
0 Hours31.16 ± 26.15782.16 ± 19.81630.16 ± 29.53627.90 ± 24.62678.48 ± 28.01774.53 ± 29.874
5 min38.02 ± 30.48578.32 ± 23.26933.14 ± 28.94831.56 ± 29.20576.60 ± 28.82472.84 ± 29.862
10 min40.42 ± 32.26578.35 ± 23.38333.52 ± 29.71332.38 ± 32.34874.86 ± 29.81264.81 ± 33.275
20 min44.54 ± 34.29675.18 ± 26.74335.46 ± 29.62233.33 ± 31.47273.46 ± 31.15162.50 ± 33.720
SecondaryAUCinf of Abrocitinib Metabolite (PF-06471658/M1) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A

Area under the plasma concentration time profile from time 0 extrapolated to infinity.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.
Reported as:
Geometric mean · ng*hr/mL
AUCinf of Abrocitinib Metabolite (PF-06471658/M1) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A
ng*hr/mLAbrocitinib 200 mg Commercial TabletFamotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet
AUCinf of Abrocitinib Metabolite (PF-06471658/M1) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A1048 ± 34903.2 ± 32
SecondaryAUCinf of Abrocitinib Metabolite (PF-07055087/M2) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A

Area under the plasma concentration time profile from time 0 extrapolated to infinity.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.
Reported as:
Geometric mean · ng*hr/mL
AUCinf of Abrocitinib Metabolite (PF-07055087/M2) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A
ng*hr/mLAbrocitinib 200 mg Commercial TabletFamotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet
AUCinf of Abrocitinib Metabolite (PF-07055087/M2) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A1369 ± 221108 ± 15
SecondaryAUCinf of Abrocitinib Metabolite (PF-07054874/M4) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A

Area under the plasma concentration time profile from time 0 extrapolated to infinity.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.
Reported as:
Geometric mean · ng*hr/mL
AUCinf of Abrocitinib Metabolite (PF-07054874/M4) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A
ng*hr/mLAbrocitinib 200 mg Commercial TabletFamotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet
AUCinf of Abrocitinib Metabolite (PF-07054874/M4) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A2139 ± 341705 ± 33
SecondaryCmax of Abrocitinib Metabolite (PF-06471658/M1) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A

Maximum observed plasma concentration.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.
Reported as:
Geometric mean · ng/mL
Cmax of Abrocitinib Metabolite (PF-06471658/M1) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A
ng/mLAbrocitinib 200 mg Commercial TabletFamotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet
Cmax of Abrocitinib Metabolite (PF-06471658/M1) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A216.8 ± 8257.38 ± 55
SecondaryCmax of Abrocitinib Metabolite (PF-07055087/M2) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A

Maximum observed plasma concentration.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.
Reported as:
Geometric mean · ng/mL
Cmax of Abrocitinib Metabolite (PF-07055087/M2) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A
ng/mLAbrocitinib 200 mg Commercial TabletFamotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet
Cmax of Abrocitinib Metabolite (PF-07055087/M2) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A214.3 ± 5856.42 ± 42
SecondaryCmax of Abrocitinib Metabolite (PF-07054874/M4) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A

Maximum observed plasma concentration.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.
Reported as:
Geometric mean · ng/mL
Cmax of Abrocitinib Metabolite (PF-07054874/M4) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A
ng/mLAbrocitinib 200 mg Commercial TabletFamotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet
Cmax of Abrocitinib Metabolite (PF-07054874/M4) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A400.5 ± 3987.96 ± 47
SecondaryNumber of Participants With Treatment-Emergent Adverse Event

Adverse events (AEs): any untoward medical occurrence in a clinical investigation participant administered a product, without regard to relatedness. Treatment-emergent AEs (TEAEs): AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Treatment-related TEAEs were any untoward medical occurrence attributed to study intervention. Relatedness to study intervention was determined by the investigator.

Time frame:
Baseline up to follow-up (Day 36)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Event
ParticipantsAbrocitinib 200 mg Commercial TabletAbrocitinib 200 mg Oral Suspension Formulation 1Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial TabletAbrocitinib 200 mg Oral Suspension Formulation 1-6Famotidine 40 mg Tablet + Abrocitinib 200 mg Oral Suspension Formulation 1-6
All-causality AEs68652
Treatment-related AEs35040
SAEs00000
SecondaryNumber of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)

Participants with laboratory abnormalities (without regard to baseline abnormality) were reported.

Time frame:
Baseline up to follow-up (Day 36)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)
ParticipantsAbrocitinib 200 mg Commercial TabletAbrocitinib 200 mg Oral Suspension Formulation 1Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial TabletAbrocitinib 200 mg Oral Suspension Formulation 1-6Famotidine 40 mg Tablet + Abrocitinib 200 mg Oral Suspension Formulation 1-6
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)00000
SecondaryNumber of Participants With Clinically Significant Vital Sign Values

Participants with clinically significant vital sign values were reported.

Time frame:
Baseline up to follow-up (Day 36)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Sign Values
ParticipantsAbrocitinib 200 mg Commercial TabletAbrocitinib 200 mg Oral Suspension Formulation 1Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial TabletAbrocitinib 200 mg Oral Suspension Formulation 1-6Famotidine 40 mg Tablet + Abrocitinib 200 mg Oral Suspension Formulation 1-6
Number of Participants With Clinically Significant Vital Sign Values00000
SecondaryNumber of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Values

Participants with clinically significant abnormal ECG values were reported.

Time frame:
Baseline up to follow-up (Day 36)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Values
ParticipantsAbrocitinib 200 mg Commercial TabletAbrocitinib 200 mg Oral Suspension Formulation 1Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial TabletAbrocitinib 200 mg Oral Suspension Formulation 1-6Famotidine 40 mg Tablet + Abrocitinib 200 mg Oral Suspension Formulation 1-6
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Values00000
SecondaryNumber of Participants With Nausea AEs

Number of participants who received abrocitinib 200 mg alone and who received abrocitinib 200 mg plus famotidine 40 mg and had nausea AEs were reported.

Time frame:
Baseline up to follow-up (Day 36)
Reported as:
Count of participants · Participants
Number of Participants With Nausea AEs
ParticipantsAbrocitinib 200 mg AloneAbrocitinib 200 mg Plus Famotidine 40 mg
Number of Participants With Nausea AEs120

Adverse events

Collected over Baseline up to follow-up (Day 36). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abrocitinib 200 mg Commercial Tablet0/18 (0%)0/18 (0%)6/18 (33.3%)
Abrocitinib 200 mg Oral Suspension Formulation 10/18 (0%)0/18 (0%)8/18 (44.4%)
Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet0/18 (0%)0/18 (0%)6/18 (33.3%)
Aborcitinib 200 mg Oral Suspension Formulation 1-60/9 (0%)0/9 (0%)5/9 (55.6%)
Famotidine 40 mg Tablet + Abrocitinib 200 mg Oral Suspension Formulation 1-60/10 (0%)0/10 (0%)2/10 (20%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventAbrocitinib 200 mg Commercial TabletAbrocitinib 200 mg Oral Suspension Formulation 1Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial TabletAborcitinib 200 mg Oral Suspension Formulation 1-6Famotidine 40 mg Tablet + Abrocitinib 200 mg Oral Suspension Formulation 1-6
NauseaGastrointestinal disorders3/185/180/184/90/10
HungerGeneral disorders1/180/180/182/90/10
Incision site complicationInjury, poisoning and procedural complications2/182/184/180/90/10
HeadacheNervous system disorders2/183/180/181/90/10
Feeling abnormalGeneral disorders0/181/180/181/90/10
Vessel puncture site painGeneral disorders0/180/181/181/90/10
AcneSkin and subcutaneous tissue disorders0/180/180/181/90/10
Abdominal pain upperGastrointestinal disorders0/180/180/180/91/10
ContusionInjury, poisoning and procedural complications0/180/180/180/91/10
Tension headacheNervous system disorders0/180/180/180/91/10

Baseline characteristics

This was a phase 1, randomized, crossover designed relative bioavailability (rBA) study conducted in healthy adult participants, including 2 parts to investigate the rBA (part A), and taste and palatability (part B) of different formulations. Participants were all healthy adults and were randomized into the study, and may or may not participate both parts of the study. Thus baseline characteristics of participants were combined.

Age, Continuous
Age, Continuous(Years)Treatment A-> B-> C-> D-> E-> F-> G-> H-> ITreatment A-> C-> B-> L-> M-> N-> B-> J-> KTreatment B-> A-> C-> K-> L-> M-> N-> B-> JTreatment B-> C-> A-> I-> D-> E-> F-> G-> HTreatment C-> A-> B-> H-> I-> D-> E-> F-> GTreatment C-> B-> A-> J-> K-> L-> M-> N-> BTotal
Mean34.3 ± 18.0134.3 ± 7.5142.3 ± 7.0242.0 ± 6.3234.7 ± 5.8643.3 ± 8.5038.7 ± 9.14
Sex: Female, Male
Sex: Female, Male(Participants)Treatment A-> B-> C-> D-> E-> F-> G-> H-> ITreatment A-> C-> B-> L-> M-> N-> B-> J-> KTreatment B-> A-> C-> K-> L-> M-> N-> B-> JTreatment B-> C-> A-> I-> D-> E-> F-> G-> HTreatment C-> A-> B-> H-> I-> D-> E-> F-> GTreatment C-> B-> A-> J-> K-> L-> M-> N-> BTotal
Female0012025
Male33223114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment A-> B-> C-> D-> E-> F-> G-> H-> ITreatment A-> C-> B-> L-> M-> N-> B-> J-> KTreatment B-> A-> C-> K-> L-> M-> N-> B-> JTreatment B-> C-> A-> I-> D-> E-> F-> G-> HTreatment C-> A-> B-> H-> I-> D-> E-> F-> GTreatment C-> B-> A-> J-> K-> L-> M-> N-> BTotal
Hispanic or Latino1300116
Not Hispanic or Latino20342213
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment A-> B-> C-> D-> E-> F-> G-> H-> ITreatment A-> C-> B-> L-> M-> N-> B-> J-> KTreatment B-> A-> C-> K-> L-> M-> N-> B-> JTreatment B-> C-> A-> I-> D-> E-> F-> G-> HTreatment C-> A-> B-> H-> I-> D-> E-> F-> GTreatment C-> B-> A-> J-> K-> L-> M-> N-> BTotal
American Indian or Alaska Native0100001
Asian0010001
Native Hawaiian or Other Pacific Islander0000000
Black or African American1122118
White2102229
More than one race0000000
Unknown or Not Reported0000000
08

Study locations

1 site
  • New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Oct 2021, 4 months.

Results were first posted in Nov 2024, 3 years after primary completion.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 4 months is below that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2021
First posted
May 26, 2021
StartActual
Jun 4, 2021
Primary completionActual
Oct 26, 2021
CompletionActual
Oct 26, 2021
Results first posted
Nov 14, 2024
Last update
Nov 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04903093
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 26, 2021
Start date
Jun 4, 2021
Primary completion
Oct 26, 2021
Completion
Oct 26, 2021
Results posted
Nov 14, 2024
Last update
Nov 14, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrocitinib

Start the discussion